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ABSTRACT
Objectives: Fatigue is recognized as the most serious compli-
cation of chemotherapy for the majority of patients. This
study aims to determine preferences and utility values for
health state descriptions of anemia associated with cancer
treatment.
Methods: FACT-An clinical trial data were summarized to
deﬁne health states associated with hemoglobin levels of 7.0–
8.0, 8.0–9.0, 9.0–10.0, 10.0–10.5, 10.5–11.0, 11.0–12.0,
and 12.0+ g/dL. Health state descriptions were reviewed by
clinicians and two quality-of-life experts. Eighty-ﬁve
members of the general public were asked to rate the health
states using a visual analogue scale and standard gamble
(SG). Twenty-six oncology patients were interviewed using
the time trade-off (TTO).
Results: The mean societal SG derived utility values showed
a signiﬁcant linear change from 0.583  0.067 (7–8 g/dL
hemoglobin [Hb]) to 0.708  0.057 (12+ g/dL Hb). The
patient TTO data ranged from 0.297  0.127 (7–8 g/dL Hb)
to 0.611  0.092 (12+ g/dL Hb).
Conclusions: The health state utility scores from both groups
show a decrement in line with worsening anemia. Further-
more, patients who have experienced cancer-related fatigue
rate the more severe levels of anemia much lower than the
general public.
Keywords: anemia, chemotherapy, fatigue, health utility,
quality of life.
Introduction
Anemia is a common experience of patients with
cancer, especially those receiving chemotherapy [1].
The disease itself is debilitating, causing fatigue,
dyspnea, and dizziness which can all affect health-
related quality of life (HRQL) [2–4]. Severely anemic
patients may no longer be able to receive chemo-
therapy which may reduce their chances of survival
and also reduce HRQL.
Fatigue is now the most serious complication of
cancer treatment when rated by cancer patients [1,5].
It is rated higher than anxiety, pain, hair loss, and
nausea [6]. In one survey, 78% of patients reported
fatigue during their disease and treatment, and 32%
complained of daily fatigue [7]. When asked which
affected their lives the most (pain, nausea, fatigue, or
depression), 60% of patients ranked fatigue the
highest, followed by nausea (22%), depression (10%),
and pain (6%) [8]. One study has shown that doctors
may value the treatment of fatigue signiﬁcantly less
than patients [7].
The fatigue of cancer treatment has only limited
overlap however with the severity of fatigue experi-
enced by the general population. Cancer patients fre-
quently experience a fatigue that is unrelieved by rest
[9]. One effective treatment for chemotherapy-related
anemia is epoetin alfa [10]. Previous studies have
examined the HRQL improvements for anemic cancer
patients treated with epoetin alfa [10]. Littlewood
et al. report a randomized trial of 375 cancer patients
which identiﬁed substantial increases in hemoglobin
(Hb) levels and improvements in HRQL over the
course of the trial. HRQL measured by the Functional
Assessment of Cancer Therapy for patients with
Anemia and/or fatigue (FACT-An) and the Medical
Outcomes Trust Short Form 36 [11] was signiﬁcantly
correlated with Hb level [10]. The FACT-An is a
validated disease-speciﬁc patient-reported outcome
measure designed to capture the burden of cancer-
related anemia [12]. It includes the four general HRQL
domains of the Functional Assessment of Cancer
Therapy—General (FACT-G) [13] and 13 additional
items which focus speciﬁcally on fatigue symptoms of
cancer-related anemia.
Crawford et al. present a reanalysis of trial data
which conﬁrmed that HRQL was associated with
increasing Hb levels [14]. Nevertheless, the correlation
with the FACT-An, although signiﬁcant, was only
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modest and the authors conclude that the relationship
is probably not linear. In a subsequent analysis, Fal-
lowﬁeld et al. conﬁrmed a strong and signiﬁcant rela-
tionship between Hb and different domains of HRQL
[15].
Patrick et al. explored the minimal important dif-
ference (MID) in HRQL related to the treatment of
anemia. The authors present a reanalysis of data from
the Littlewood trial [4]. An Hb increase of 1 g/dL was
used to benchmark the MID. A MID for the FACT-G
of 2.54 and for the FACT-An of 4.24 was determined.
The improvements seen in the erythropoietin group
exceeded this benchmark, leaving the authors to con-
clude the treatment produced clinically signiﬁcant
improvements in HRQL.
One of the shortcomings of Patrick et al.’s study is
that it is based on the assumption that a 1 g/dL change
in Hb is a signiﬁcant change from both the physicians’
and patients’ perspectives. This degree of change may
be clinically signiﬁcant in terms of patient management
and developing treatment guidelines for the use of
blood products, but it does not tell us whether a 1 g/dL
change in Hb is an important change for the patient. It
may be that a smaller change in Hb is important for
patients, or maybe much larger changes are required
for a patient to recognize beneﬁt. Furthermore, this
approach is not able to differentiate the relative impor-
tance of unit improvements in Hb from different base-
line points. Is a shift from 9 to 10 g/dL of the same
importance as a shift from 11 to 12 g/dL? These shifts
probably do have different relevance both from the
patients’ perspective and clinically.
One method to understand the importance of dif-
ferences in Hb level is by eliciting health utilities for
each health state. Utilities can be combined with sur-
vival data in the determination of quality-adjusted life-
years to support a cost-effectiveness analysis. Such
analyses can be used to guide resource allocation deci-
sions. In the context of a publicly funded health-care
system, the utility values for health states should reﬂect
the values of the public. The general public may,
however, underestimate the importance or signiﬁcance
of fatigue because tiredness and fatigue is experienced
by everyone from time to time. The important distinc-
tion, however, is that the fatigue in this context is not
relieved by rest, and as outlined above, is one of the
most signiﬁcant side effects of treatment as rated by
patients. Only people who have experienced this
fatigue can really know what it is like and only these
people have fully constructed preferences regarding
cancer-related fatigue. Therefore, we hypothesized that
such a population will place a greater value on the
treatment of fatigue than the general population.
The present study was designed to elicit preferences
for health states related to different levels of Hb in the
context of cancer-related anemia. Different methods
(standard gamble [SG] or time trade-off [TTO]) can be
used for determining participants’ strength of prefer-
ence for a health state in the context of death and
perfect health. The elicitation of utilities indicates not
only if one health state is preferred to another, but it
also indicates by how much a health state is preferred
to another health state. Therefore, by estimating utility
it is possible to determine how important differences in
Hb levels are for the participants in the study. The
present study reports the preferences of a UK societal
sample in addition to a group of oncology patients
with recent experience of chemotherapy-related
anemia and fatigue.
Methods
Development of Health States
Health state descriptors were developed based on the
health status and HRQL proﬁle of patients with
known levels of Hb. Clinical trial data from Little-
wood et al. were reanalyzed [10] by classifying
patients (placebo and active treatment) into groups
based on their Hb level (e.g., 7.0–8.0, 8.0–9.0, 10.0–
10.5, 10.5–11.0, 11.0–12.0, and 12.0+ g/dL). The fre-
quency of each response level for each question on the
FACT-An was determined by Hb group. The items in
the FACT-An include ﬁve response choices from “not
at all,” “a little bit,” “somewhat,” “quite a bit” to
“very much.” The intention was to use these quantiﬁ-
ers to differentiate the health states (e.g., “I feel some-
what tired” or “I feel tired very much”).
This process revealed that some items from the
FACT-An were very sensitive to changes in Hb whereas
others did not vary greatly between the groups. The
following items (“I am too tired to eat,” “I need to
sleep during the day,” and “I have energy”) did not
vary greatly between the levels of anemia and so they
were not included in the ﬁnal health state descriptions.
Some questionnaire items were combined so that the
health states were not too repetitive (e.g., “I have
trouble starting things because I am tired” and “I have
trouble ﬁnishing things because I am tired”).
The ﬁrst-draft health states were considered to be
complex, too long, and too repetitive by the study
team. Following a review of the health state descrip-
tions, some of the elements of the health states were
merged into the same bullet point to simplify them.
The response categories (“not at all” and “somewhat,”
etc.) did not work well as quantiﬁers in the health
states. Through discussion with external reviewers it
was decided, therefore, that the occurrence of tiredness
or fatigue could be described in terms of the number of
days per week that the patient can be affected.
The revised-draft health states were then reviewed
for face and content validity by four experts: an oncol-
ogy specialist nurse and two oncologists, including one
with special expertise in measuring HRQL and a psy-
chometrician with expertise in utility studies. One of
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the experts did express some concerns regarding how
the health states varied in terms of the number of days
per week that they could expect to experience these
symptoms. Therefore, the health states were changed
so that they varied by severity of symptoms as well as
frequency. During the later patient-based phase of the
study, ﬁve of the patients completed an additional
interview to review the content validity of the health
states. All of these participants conﬁrmed that they
considered the health states to be accurate descriptions
of cancer-related fatigue. The health states were not
labeled or identiﬁed as descriptions of cancer.
Pilot Study
The health states were piloted with ﬁve members of the
general public (recruited from newspaper advertise-
ments) in a conventional SG interview. At the end of
the interview participants took part in a cognitive
debrieﬁng exercise to assess the clarity of the health
states. Some minor changes to the health states were
made following feedback received to clarify what was
meant by certain statements. Revised health states
were then piloted again with six participants before the
main study. This second pilot process did not reveal
any additional issues to be addressed.
Societal Valuation Study
In total, 87 members of the general public were
recruited (through newspaper advertisements) to
provide estimates of utility for the anemia-related
health states (data were available for 83 participants, 4
other people could not understand the task). All inter-
views were conducted by trained interviewers at the
UBC London ofﬁces. All participants provided written
informed consent and completed a sociodemographic
questionnaire providing details of age, ethnicity, sex,
education, and employment status. Participants
were also asked to complete the EQ-5D, a generic
preference-based HRQL measure [16]. HRQL data
from a representative UK sample are available for this
instrument [17].
The SG interview included a visual analogue scale
(VAS) task and the SG utility method [18, 19]. Partici-
pants rated each health state (and their own current
health) on the VAS which had a lowest anchor value of
zero (death) and a highest anchor value of 100 (perfect
health), before completing the SG task. At the end, the
participant was permitted to alter rankings until satis-
ﬁed that the relative and absolute rankings accurately
reﬂected his/her preferences.
The participants were administered the SG task for
the same set of hypothetical health states and their
own current health. For each health state, participants
were asked to choose one of three options: 1) to live in
the hypothetical health state with certainty for the rest
of their lives; 2) to choose between various probabili-
ties of having either perfect health or worst health for
the rest of their lives; or 3) to indicate that the two
previous options were equal. Probabilities for option 2
were varied sequentially until the patient was indiffer-
ent about the choices. High and low probabilities of
perfect health and the worst health state were alter-
nated to avoid anchoring bias [19]. Finally, the worst
health state was assessed using the SG, based on a
gamble between dead and perfect health. The utility
value for the worst state was used to recalibrate the
utilities for the health states on this dead to perfect
health scale.
Patient Valuation Study
A revised protocol was developed to describe the
recruitment and interviewing of patients who have
experienced chemotherapy-related fatigue. The patient
protocol was very similar to the societal protocol.
Extra data were collected regarding patients’ clinical
characteristics. Patients were asked to rate their health
during their last round of chemotherapy and to choose
which card best described what they felt like during
their last round of chemotherapy. This additional task
was designed to provide some validity data regarding
the health states. The last round of chemotherapy was
chosen because it is recognized that chemotherapy-
related anemia may continue to get worse as patients
undergo more rounds of treatment, and also it was felt
that patients would be able to recall their last round
most clearly. The protocol was approved by the local
research ethics committee in Bath, United Kingdom.
To be eligible for the study, patients must have
undergone chemotherapy for more than 12 weeks
within the last year, and must have become at least
mildly anemic (Hb < 11 g/dL) at some point during
their chemotherapy. The following criteria excluded
patients from being eligible: presence of acute illness,
or cognitive or other impairment (e.g., visual) that in
the opinion of the site investigator would interfere
with the study requirements; considered too ill to be
interviewed; history of substance or alcohol abuse (as
determined from the medical notes); recent relapse or
recurrence of cancer as reported by patient or identi-
ﬁed from the medical notes; or currently undergoing
chemotherapy.
In total, 171 patients were screened. Of these 49
patients matched the study entry criteria and were
invited to participate. Twenty-nine patients agreed to
take part and all attended. Three interviews were ter-
minated by the interviewer because of problems
reading the health states (n = 2), and inability to
imagine living in the described health states (n = 1).
A small pilot study was conducted to determine the
appropriateness of the interview methodology and
study materials. The pilot study was stopped after
three participants had completed it because of negative
feedback regarding the SG interview. Participants were
unhappy at being asked to make choices where pros-
1180 Lloyd et al.
pects involved the risk of immediate death. Therefore,
a decision was made to switch the utility interview
format to TTO (approval for which was granted by the
local research ethics committee).
All participants were offered a £25 gift or an oppor-
tunity to make a donation to the cancer charity Cancer-
backup (http://www.cancerbackup.org) of £25 on their
behalf and all of them chose to make the donation.
Statistical Analysis
The demographic and HRQL characteristics of the
societal sample were compared to data from the UK
census [20] and EQ-5D national survey data [17].
Utility data were summarized descriptively. The health
state valuations were also tested to determine whether
the values differed signiﬁcantly from each other. This
was undertaken using a one-way analysis of variance
(ANOVA) with post hoc tests least signiﬁcant differ-
ences (LSD) to explore differences between health
states.
Results
Participant Characteristics
The participant demographic data from the societal
and patient survey are presented in Table 1. The soci-
etal sample was a relatively good match to the national
census data. The sample was slightly older than the
mean national age and more ethnically diverse [17].
The UK census data describe the proportion of people
who are employed full-time, part-time, or self-
employed which includes 44% of the population. This
is a little lower than the 52% who fall into this group
in our sample.
Patients had the following primary cancers: breast
(54%), colorectal (15%), ovarian (11.5%), and lym-
phoma (11.5%). Eight percent of the patient sample
suffered from metastatic disease. The most recent
minimummean Hb level recorded was 11.89 (standard
deviation [SD] 9.30) while patients’ mean lowest
recorded Hb level was 10.33 (SD 7.50). This had been
treated with transfusions (19%) but not erythropoietin.
HRQL Proﬁle
Societal data. The self-reported HRQL proﬁle of the
societal sample was characterized in terms of moderate
or severe problems on the ﬁve dimension of the EQ-5D
(Table 2). The distribution of moderate and extreme
problems recorded by the EQ-5D in the present study
is a relatively close match to the UK National Survey
[17]. The present study may under-represent partici-
pants with problems with mobility and self-care, when
compared to Kind et al.’s sample. This may reﬂect
differences in methodology whereby Kind et al. used
a postal survey and the present study interviewed
participants.
In addition to the EQ-5D data regarding the general
public’s HRQL, the utility interview also evaluated
current health. The mean EQ-VAS score for current
health was 81.6 (SD 14.9) and the mean SG utility
score for current health was 0.90 (SD 0.12).
Table 1 Participants’ demographic proﬁle, including experience of serious illness
Study sample (n = 85) Patients (n = 26) UK census and ONS data 2001–2004
Age: mean (SD) 44.0 (15.6) 59.7 (11.3) 38.2
Sex: N/Tot (% female) 48/85 (57%) 21/26 (81%) 51%
Ethnic group
White 70 (83%) 24 (92%) 92.1%
Black 3 (4%) 1 (4%) 2.0%
Asian 7 (8%) 4.0%
Other (including mixed race, Jewish, Irish) 4 (5%) 1 (4%) 1.9%
Employment status
Full-time 15 (17%) 5 (19%)
Part-time 21 (25%) 7 (27%) Full-/part-time and self-employed
Self-employed 9 (10%) 0 43.6%
Seeking work 13 (15%) 0 4.8%
Homemaker 5 (6%) 3 (12%) 4.6%
Disabled 2 (2%) 0 4.2%
Retired 10 (12%) 11 (42%) 9.8%
Student 9 (10%) 0 1.9%
Other 2 (3%) 0 2.3%
Education—leaving age
Secondary school (16 or below) 14 (17%) 13 (52%)
18 years (A levels) 27 (37%) 2 (8%)
University degree/vocational training 31 (37%) 11 (40%)
Postgraduate degree 12 (14%)
Participants’ experience of serious illness
Participant themselves 22 (26%) —
Participants’ family 59 (71%) —
In caring for others 37 (46%) —
N/Tot, number out of the total sample; ONS, Ofﬁce of National Statistics; SD, standard deviation.
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Health State Utility Values
Societal data. Table 3 shows the mean societal utility
scores from the VAS and SG tasks for the anemia
health states. Mean scores for the VAS ranged from
16.9 for an Hb level of 7–8 g/dL and increased incre-
mentally with each increase of Hb to a score of 51.2
for a 12+ g/dL Hb level. A one-way ANOVA revealed
that VAS preference values increased signiﬁcantly in
line with rising Hb levels (F = 50.2, P < 0.001). Post-
hoc tests revealed that each health state was signiﬁ-
cantly different from every other health states.
Mean SG ratings increased in line with increasing
Hb levels. Mean SG utility scores ranged from 0.583
for an Hb level of 7–8 g/dL to 0.708 for a 12+ g/dL Hb
level. The one-way ANOVA revealed that there was
signiﬁcant variance in scores between the health states
(F = 2.2, P = 0.04), but the post hoc tests indicated
that only the extreme states were signiﬁcantly different
to each other (e.g., the worst two states were signiﬁ-
cantly worse than the best two states).
Patient data. The pattern of VAS and TTO derived
health state values from the patient interviews con-
trasted with the societal data. Mean scores for the VAS
ranged from 21.7 for an Hb level of 7–8 g/dL and
increased incrementally with each increase of Hb to a
score of 62.4 for a 12+ g/dL Hb level (F = 15.39,
P < 0.001). Post hoc tests revealed that each health
state was at least different to a health state two steps
below (i.e., 9–10 g/dL was signiﬁcantly different to
7–8 g/dL), but adjacent health states were not signiﬁ-
cantly different. These absolute values and range are
similar to the societal values. Mean TTO utility scores
ranged from 0.297 for an Hb level of 7–8 g/dL to
0.611 for a 12+ g/dL Hb level. The utility values for
the more severely anemic health states were much
lower in the patient study compared to the societal
sample. TTO-derived utility values increased signiﬁ-
cantly in line with rising Hb levels (F = 2.97,
P = 0.009). Post hoc tests revealed that only the
extreme values were signiﬁcantly different from each
other (i.e., 7–8 g/dL was different to 11–12 and 12+ g/
dL) (Table 4).
The mean utility value that patients attributed to
their HRQL during their last round of chemotherapy
was 0.643 (TTO) and 38.6 (VAS). The mean Hb level
for patients at the end of the study was 11.9, indicating
that anemia levels were low. Participants were most
likely to choose the card describing 10.5–11.0 g/dL as
being closest to how they felt at the end of the chemo-
therapy. There was generally, however, a poor mapping
between patients’ actual Hb level and the card they
chose which was closest to how they felt.
Discussion
This study reports the utility that the public and cancer
patients place on different levels of cancer-related
anemia and fatigue. Health state descriptions were
developed from clinical trial data from patients with
anemia related to cancer. These health state descrip-
tions were reviewed by patients and clinical experts
and were piloted. Members of the general public in the
utility study were able to recognize the differences
between the health states and these differences were
Table 2 General public participants’ ratings of their current health from the EQ-5D compared to data from a national survey reported
by Kind [17]
Dimension
Community sample Kind [17]
Moderate problem (%) Extreme problem (%) Moderate problem (%) Extreme problem (%)
Mobility 8.2 0 18.3 0.1
Self-care 0 0 4.1 0.1
Usual activity 15.3 0 14.2 2.1
Pain/discomfort 29.4 1.2 29.2 3.8
Anxiety/depression 23.5 2.4 19.1 1.8
Table shows proportion of people reporting moderate or extreme problems on each dimension.
Table 3 Societal standard gamble and VAS ratings for the study health state descriptions
Health state (by Hb level) Mean standard gamble utility 95% CI Mean VAS 95% CI
7.0–8.0 g/dL 0.583 0.067 16.9 2.6
8.0–9.0 g/dL 0.608 0.064 22.3 3.0
9.0–10.0 g/dL 0.640 0.060 27.6 2.9
10.0–10.5 g/dL 0.642 0.062 32.9 3.4
10.5–11.0 g/dL 0.661 0.061 38.8 3.6
11.0–12.0 g/dL 0.703 0.056 45.9 4.2
12.0+ g/dL 0.708 0.057 51.2 4.3
Table shows mean and 95% conﬁdence intervals (95% CI).
CI, conﬁdence interval; Hb, hemoglobin;VAS, visual analogue scale.
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important to people. The gain in health utility moving
from an Hb level of 7–8 g/dL to 12.0+ g/dL is equiva-
lent to moving from 0.58 to 0.71 on the 0–1 scale. This
is a relatively substantial utility gain, and reﬂects the
importance that the public place on the avoidance of
cancer-related fatigue.
The patient survey also represented an opportunity
to partially validate the health state descriptions. This
exercise focused on the last round of chemotherapy
whereby people were asked to rate their health at this
time and also select the health state description which
was closest to how they felt. This provided some data
to support the validity of the health state descriptions.
When patients rated their last round of chemotherapy
the mean utility value was 0.643, when they actually
had an Hb level of 11.88. The 11–12 g/dL health state
was rated at 0.545. The higher utility values for the
last round of chemotherapy may have resulted from
the fact that patients knew it was their last round of
treatment and so they were better able to cope with the
impact of it. With hindsight it may have been better to
choose a different round of chemotherapy.
Patients’ ratings of their last round of chemotherapy
did not tally well with the ratings for their level of Hb
at that time. Also patients were not really able to
accurately identify a health state which matched their
Hb level at the last round of chemotherapy. Asking
patients to identify a health state that matches their
previous Hb level may be an unrealistically tough test
of validity. There are a lot of variables, other than their
Hb level, such as metastatic status, anticipated prog-
nosis, and extent of disease that will have inﬂuenced
their quality of life at that time.
There is a potential limitation of this study related
to our need to switch the utility elicitation methods
from SG in the general public survey to TTO for the
patient study. The study team believed that there was a
strong case for this from the response to the SG exer-
cise among the patients in the pilot study. By working
with the local ethics committee we were able to come
up with a compromise solution which involved con-
tinuing data collection using the TTO method. It is
possible, however, that this may partly explain the
differences in the utility values for health states from
the two groups. It is well recognized that TTO and SG
do not give identical utility values [21]. Nevertheless,
we do not believe that the change in methodology can
fully explain the pattern of results. A change in method
is most likely in our view to cause a systematic error in
the data which equally inﬂates or deﬂates all of the
values—thus leading to parallel lines. We found,
however, that the greatest difference in utilities
between the public and patients was for the most
severe health states (Figs. 1 and 2). Other studies have
contrasted values for health using different techniques
(SG, TTO, VAS, and willingness to pay). Kontodi-
mopoulos and Niakas report SG and TTO values from
the same patients with renal failure and report that the
SG values were considerable higher than TTO [22].
Nevertheless, there is no evidence that we are aware of
to indicate this effect varies by the severity of the state.
The data collected from the oncology patients who
had all experienced cancer-related anemia provided an
interesting contrast to the societal valuation survey
(Fig. 1). Kostopoulou refers to a “well known ﬁnding”
that patients tend to assign higher utilities to their
health state than the general public do [23]. Neverthe-
less, the present ﬁndings are an example where this is
not the case. The patients in the present study placed a
greater weight (or disutility) on the impact of fatigue.
Their utility values for the more severe states were
considerably lower than the equivalent values from the
societal valuation study (see Fig. 1). This supported
our hypothesis that patients would place a much
greater value on the avoidance of fatigue when com-
pared to society. As discussed previously, the fatigue
experienced as a result of chemotherapy treatment is
qualitatively different to the fatigue that everyone
experiences occasionally. The patients in this study had
all experienced this type of fatigue in the past and so
recognized the seriousness of it when presented with
the health state descriptions. In contrast, the members
of the general public did not perhaps appreciate the
severity of this level of cancer-related fatigue.
The differences between the public and patient utili-
ties have some implications for the debate around
whether the general public or patients should be used
for estimating utility weights. The arguments for elic-
Table 4 Mean patient time trade-off utility andVAS values for the study health state descriptions, plus EQ-5D ratings of current health
Health state Mean time trade-off utilities 95% CI Mean VAS value 95% CI
7.0–8.0 g/dL 0.297 0.127 21.7 5.7
8.0–9.0 g/dL 0.360 0.126 32.4 6.6
9.0–10.0 g/dL 0.408 0.125 34.2 6.7
10.0–10.5 g/dL 0.446 0.122 41.9 6.6
10.5–11.0 g/dL 0.454 0.111 44.7 6.6
11.0–12.0 g/dL 0.545 0.105 52.2 6.8
12.0+ g/dL 0.611 0.112 62.4 7.9
Own current health 0.851 0.034 87.6 4.9
EQ-5D current health 0.872 0.076 84.19 4.57
CI, conﬁdence interval;VAS, visual analogue scale.
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iting the preferences of the general public in utility
studies are very sound where these data are to be used
to guide the allocation of public money. Nevertheless,
the current study suggests that some patient groups
may not get access to health technologies because the
public may fail to recognize or value the severity of
their condition. Such a lack of recognition of the sever-
ity of a health state could also occur in other disease
areas—severe chronic pain or mental health condi-
tions. If reimbursement authorities believed that the
societal preferences did not reﬂect the clinical severity
of a state, then sensitivity analyses based on patient
preference data could usefully support the decision-
making process in addition to the main analyses or
reference case.
For centrally planned health services, such as the
United Kingdom National Health Service, new cancer
funding has been targeted to focus on the most press-
ing problems of improving survival rates and replacing
capital equipment [24,25]. Continuity of care for
longer-term care programs was seen predominantly in
terms of palliative care. The impact on local decision-
makers in many centralized health services has been
that drug funds have been prioritized for use on
survival-enhancing interventions, with few resources
left for short- and longer-term supportive care targeted
primarily on improving quality of life. Within support-
ive care, resources are particularly limited for funding
treatments such as erythropoietin for the management
of cancer-related anemia, a common and very debili-
tating side effect of intensive therapy. This was one
of the reasons for the European Organization for
Research and Treatment of Cancer producing central
guidelines on the management of cancer anemia [26].
The prevalence of cancer is rising markedly because
of increased survival rates. This has created a new
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Figure 2 Societal and patient preferences for
the anemia health states elicited by visual ana-
logue scale. Hb, hemoglobin.
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challenge of reducing disability and improving quality
of life. Patients rate fatigue associated with anemia as
one of the most debilitating effects of their cancer and
its treatment. This study shows that patients may value
supportive care higher than general society does. This
has signiﬁcant implications when choosing how
central health funds for cancer are prioritized.
Acknowledgments
This work was presented at the Society for Medical
Decision Making Europe 10th Biennial European
Meeting, June 11 to 13, 2006, Birmingham, United
Kingdom. It was supported by OrthoBiotech Ltd.,
High Wycombe, United Kingdom.
Reference
1 Stone P, Richards M, Hardy J. Fatigue in patients with
cancer. Eur J Cancer 1998;34:1670–6.
2 Winningham ML, Nail LM, Burke MB, et al. Fatigue
and the cancer experience: the state of the knowledge.
Oncol Nurs Forum 1994;21:23–36.
3 Cella D. Factors inﬂuencing quality of life in cancer
patients: anemia and fatigue. Semin Oncol
1998;25:43–6.
4 Patrick DL, Gagnon DD, Zagari MJ, et al. Assessing
the clinical signiﬁcance of health-related quality of life
(HrQOL) improvements in anaemic cancer patients
receiving epoetin alfa. Eur J Cancer 2003;39:335–45.
5 Simon AM, Zittoun R. Fatigue in cancer patients.
Curr Opin Oncol 1999;11:244–9.
6 Ashbury FD, Findlay H, Reynolds B, McKerracher
KA. Canadian survey of cancer patients’ experiences:
are their needs being met? J Pain Symptom Manage
1998;16:298–306.
7 Vogelzang NJ, Breitbart W, Cella D, et al. Patient,
caregiver, and oncologist perceptions of cancer-related
fatigue: results of a tripart assessment survey. The
Fatigue Coalition. Semin Hematol 1997;34:4–12.
8 Curt GA, Breitbart W, Cella D, et al. Impact of
cancer-related fatigue on the lives of patients: new
ﬁndings from the Fatigue Coalition. Oncologist
2000;5:353–60.
9 Cella D, Davis K, Breitbart W, Curt G Cancer-related
fatigue: prevalence of proposed diagnostic criteria in a
United States sample of cancer survivors. J Clin Oncol
2001;19:3385–91.
10 Littlewood TJ, Bajetta E, Nortier JW, et al. Effects of
epoetin alfa on hematologic parameters and quality of
life in cancer patients receiving nonplatinum chemo-
therapy: results of a randomized, double-blind,
placebo-controlled trial. J Clin Oncol 2001;19:2865–
74.
11 Ware JE, Snow KK, Kosinski M, Gandek B. SF-36
Health Survey Manual and Interpretation Guide.
Boston MA: New England Medical Centre, 1993.
12 Yellen SB, Cella DF, Webster K, et al. Measuring
fatigue and other anemia-related symptoms with the
Functional Assessment of Cancer Therapy (FACT)
measurement system. J Pain Symptom Manage
1997;13:63–74.
13 Cella DF, Tulsky DS, Gray G, et al. The Functional
Assessment of Cancer Therapy Scale: development
and validation of the general measure. J Clin Oncol
1993;11:570–9.
14 Crawford J, Cella D, Cleeland CS, et al. Relationship
between changes in hemoglobin level and quality of
life during chemotherapy in anemic cancer patients
receiving epoetin alfa therapy. Cancer 2002;95:888–
95.
15 Fallowﬁeld L, Gagnon D, Zagari M, et al. Multivari-
ate regression analyses of data from a randomised,
double-blind, placebo-controlled study conﬁrm
quality of life beneﬁt of epoetin alfa in patients re-
ceiving non-platinum chemotherapy. Br J Cancer
2002;87:1341–53.
16 Brooks R. EuroQol: the current state of play. Health
Policy 1996;37:53–72.
17 Kind P, Dolan P, Gudex C, Williams A. Variations in
population health status: results from a United
Kingdom national questionnaire survey. BMJ
1998;316:736–41.
18 Torrance GW. Measurement of health state utilities
for economic appraisal. J Health Econ 1986;5:1–30.
19 Bennett KJ, Torrance GW. Measuring health status
preferences and utilities: rating scale, time trade-off,
and standard gamble techniques. In: Spilker B, ed.
Quality of Life and Pharmacoeconomics in Clinical
Trials (2nd ed.). Philadelphia, PA: Lippincott-Raven,
1996.
20 Ofﬁce of National Statistics Population of the United
Kingdom: by ethnic group, April 2001. [Online].
Available from: http://www.statistics.gov.uk/cci/
nugget_print.asp?ID=764 [Accessed July 17, 2005].
21 Brazier J, Ratcliffe J, Salomon J, et al. Measuring and
Valuing Health Beneﬁts for Economic Evaluation.
Oxford: Oxford University Press, 2007.
22 Kontodimopoulos N, Niakas D. Overcoming inherent
problems of preference-based techniques for measur-
ing health beneﬁts: an empirical study in the context
of kidney transplantation. BMC Health Serv Res
2006;6:3.
23 Kostopoulou O. The transient nature of utilities
and health preferences. Med Decis Making
2006;26:304–6.
24 National Health Service Department of Health. The
National Health Service (NHS) Cancer Plan: a plan
for investment, a plan for reform. Available from:
http://www.dh.gov.uk/assetRoot/04/01/45/13/
04014513.pdf [Accessed October 3, 2005.
25 Bosanquet N, Tolley K. Treatment of anemia in cancer
patients: implications for supportive care in the
National Health Service Cancer Plan. Curr Med Res
Opin 2003;19:643–50.
26 Bokemeyer C, Aapro MS, Courdi A, et al. EORTC
guidelines for the use of erythropoietic proteins
in anaemic patients with cancer. Eur J Cancer
2004;40:2201–16.
Health State Utility for Cancer-Related Anemia 1185
